← back to search

Sagi Tamir

Hebrew University of Jerusalem · IL
Area of research
Renewable Energy, Sustainability and the Environment · Molecular Biology
Research interest
Research interests include Autophagy, Cancer research, Chemistry, Mitochondrion, Cell biology, and Cancer cell.
h-index
citations
874
works
11
NIH funding
primary concept
email

Recent publications

The anti-apoptotic proteins NAF-1 and iASPP interact to drive apoptosis in cancer cells
Chemical Science 2018cited by 12position: middledoi
Interactions between mitoNEET and NAF-1 in cells
PLoS ONE 2017cited by 53position: middledoi
Breast cancer tumorigenicity is dependent on high expression levels of NAF-1 and the lability of its Fe-S clusters
Proceedings of the National Academy of Sciences 2016cited by 82position: middledoi
The Fe-S cluster-containing NEET proteins mitoNEET and NAF-1 as chemotherapeutic targets in breast cancer
Proceedings of the National Academy of Sciences 2015cited by 81position: middledoi
Activation of apoptosis in NAF-1-deficient human epithelial breast cancer cells
Journal of Cell Science 2015cited by 60position: middledoi
Structure–function analysis of NEET proteins uncovers their role as key regulators of iron and ROS homeostasis in health and disease
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2014cited by 203position: firstdoi
Integrated strategy reveals the protein interface between cancer targets Bcl-2 and NAF-1
Proceedings of the National Academy of Sciences 2014cited by 62position: firstdoi
A point mutation in the [2Fe–2S] cluster binding region of the NAF-1 protein (H114C) dramatically hinders the cluster donor properties
Acta Crystallographica Section D Biological Crystallography 2014cited by 42position: firstdoi
NAF-1 and mitoNEET are central to human breast cancer proliferation by maintaining mitochondrial homeostasis and promoting tumor growth
Proceedings of the National Academy of Sciences 2013cited by 221position: middledoi
Nutrient-Deprivation Autophagy Factor-1 (NAF-1): Biochemical Properties of a Novel Cellular Target for Anti-Diabetic Drugs
PLoS ONE 2013cited by 47position: firstdoi
Development of targeted therapy for a broad spectrum of solid tumors mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P4 and IGF2-P3 regulatory sequences.
PubMed 2013cited by 11position: middle

Grants

No grants ingested yet.

Frequent collaborators

Ron Mittler · Hebrew University of Jerusalem10 papers (2013–2018)Patricia A. Jennings · University of San Diego10 papers (2013–2018)Rachel Nechushtai · Hebrew University of Jerusalem10 papers (2013–2018)José N. Onuchic · Center for Theoretical Biological Physics8 papers (2013–2018)Yang‐Sung Sohn · Hebrew University of Jerusalem7 papers (2013–2018)Mark L. Paddock · University of California San Diego7 papers (2013–2015)Luhua Song · University of North Texas6 papers (2013–2018)Colin H. Lipper · Harvard University5 papers (2013–2015)Sarah H. Holt · Virginia Tech5 papers (2013–2017)Ola Karmi · Hebrew University of Jerusalem4 papers (2015–2018)Faruck Morcos · The University of Texas at Dallas4 papers (2014–2017)Andrea R. Conlan · University of California San Diego4 papers (2013–2014)Merav Darash Yahana · Hebrew University of Jerusalem4 papers (2015–2017)Fang Bai · ShanghaiTech University4 papers (2015–2018)Dorit Michaeli · Hebrew University of Jerusalem4 papers (2013–2015)Yuting Luo · Sun Yat-sen University3 papers (2015–2017)Abraham Hochberg · Hebrew University of Jerusalem2 papers (2013–2013)Eli Pikarsky · Hadassah Medical Center2 papers (2015–2016)Yael Harir · Hebrew University of Jerusalem2 papers (2013–2013)Jason T. Stofleth · Ajinomoto (United States)2 papers (2014–2014)